Xenon Pharmaceuticals (NASDAQ:XENE) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11), Zacks reports. During the same period last year, the company earned ($0.84) EPS.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock traded up $0.34 on Thursday, reaching $44.92. 709,123 shares of the stock were exchanged, compared to its average volume of 917,995. The stock has a market cap of $3.47 billion, a PE ratio of -11.55 and a beta of 0.96. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $46.60. The stock has a 50 day moving average price of $42.51 and a 200 day moving average price of $40.94.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on XENE shares. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Wells Fargo & Company raised their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Thursday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $55.17.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 65,302 shares of company stock valued at $2,924,128 in the last quarter. 4.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Freestone Grove Partners LP acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at approximately $271,000. Virtus Investment Advisers LLC grew its holdings in Xenon Pharmaceuticals by 74.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 2,568 shares during the period. Magnetar Financial LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $231,000. Cibc World Markets Corp bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $225,000. Finally, Mackenzie Financial Corp acquired a new stake in Xenon Pharmaceuticals in the fourth quarter worth $210,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.